For most aged-care and hospital nutrition assessment programs, the right answer is BIA — not because it is more accurate than DXA, but because it is the only method that is operationally deployable at scale in those settings. DXA remains the technical gold standard for body-composition measurement, but a gold standard that is unavailable at the point of care is not a usable standard. This procurement guide explains the tradeoffs, maps the clinical evidence, and provides the framework for choosing the right modality for your facility's specific context.

What is the clinical difference between BIA and DXA for nutrition assessment?

DXA — dual-energy X-ray absorptiometry — measures body composition by passing two X-ray beams at different energy levels through the body and calculating the differential attenuation to estimate fat mass, lean mass, and bone mineral content. It is highly reproducible, provides regional body-composition data (limb lean mass is particularly relevant to sarcopenia assessment), and its outputs are widely accepted as reference values in clinical research and guideline development.

BIA — bioimpedance analysis — estimates body composition by measuring the electrical impedance of the body to a small alternating current. Fat tissue and lean tissue have different electrical conductivity properties, allowing the device to estimate the ratio of fat to lean mass through validated regression equations. BIA does not measure bone mineral content. Its accuracy is sensitive to hydration status, and measurements are less precise at the individual patient level than DXA, particularly in patients with oedema, ascites, or significant dehydration.

For nutrition assessment in aged care, the relevant clinical questions are: is the patient malnourished or at risk of malnutrition, is muscle mass low enough to suggest sarcopenia, and is the patient's nutritional status responding to intervention? For these screening and monitoring questions, BIA is clinically adequate when a validated device is used correctly. For research-grade phenotyping, individual-level diagnostic precision, or bone health assessment, DXA is required.

What does EWGSOP2 say about BIA for sarcopenia assessment?

The European Working Group on Sarcopenia in Older People published its updated consensus guidelines (EWGSOP2) in 2019. The EWGSOP2 algorithm identifies low muscle mass, low muscle strength, and low physical performance as the three components of sarcopenia diagnosis. For measuring muscle mass, EWGSOP2 lists DXA, BIA, CT, and MRI as accepted methods — but notes that in clinical practice, DXA and BIA are the most practical.

EWGSOP2 explicitly states that BIA is a valid alternative to DXA when DXA is unavailable and that population-specific and device-specific validation data should be considered when selecting a BIA device. This is the clinical authorisation that most aged-care procurement teams need to justify BIA purchase: it is not a compromise; it is the guideline-recommended modality for settings without DXA access. The requirement for population-specific validation is also a procurement specification — it means the device must have published validation data in older populations, not just in general adult or athletic populations.

Side-by-side procurement comparison

Dimension	BIA	DXA
Measurement principle	Electrical impedance estimation	Dual-energy X-ray attenuation
Individual precision	Moderate — affected by hydration	High — minimal day-to-day variability
Outputs	Fat mass, lean mass, body water, phase angle	Fat mass, lean mass, bone mineral content, regional data
Bone mineral density	Not available	Available — gold standard
Point-of-care use	Yes — bedside, ward, community	No — fixed installation required
Installation requirements	None — plug-in device	Radiation shielding, dedicated room
Radiation exposure	None	Very low ionising radiation
Staff training required	Low — nursing or allied health operable	High — radiographic or DXA-trained technician
Throughput	High — measurement takes minutes	Lower — scan plus positioning time
Capital cost (indicative range)	Lower — clinical BIA varies widely by device class	Substantially higher, plus installation cost
EWGSOP2 endorsement	Yes — accepted alternative	Yes — primary reference method
Regulatory class (Canada)	Class II — MDL required	Class III — more intensive regulatory review

When does DXA make sense in a hospital or aged-care context?

DXA is the appropriate procurement choice when a facility already has DXA infrastructure in place for bone mineral density assessment and can extend its use to body composition at marginal incremental cost. In large acute hospitals with radiology departments operating DXA for osteoporosis management, adding body-composition scan protocols to existing workflow is often operationally straightforward and avoids the need for a separate BIA procurement.

DXA is also appropriate when the clinical use case requires individual-level precision — for example, in oncology departments monitoring cachexia progression where small changes in lean mass are clinically significant, or in research programs where DXA outputs will be published or compared against normative datasets. For aged-care facilities operating under routine residential care conditions without existing DXA access, the capital, installation, and staffing costs of DXA are difficult to justify against the clinical marginal gain over validated BIA.

Multi-frequency vs single-frequency BIA: a procurement distinction

Within the BIA category, procurement teams face a secondary choice: single-frequency versus multi-frequency (bioelectrical impedance spectroscopy, BIS) devices. Single-frequency devices apply current at one frequency (typically 50 kHz) and use population regression equations to estimate body compartments. Multi-frequency devices apply current across a range of frequencies, allowing the device to model the frequency-impedance relationship and estimate intracellular and extracellular water separately.

For aged-care settings, multi-frequency BIA has practical advantages in patients with abnormal fluid distribution. Elderly patients with heart failure, chronic kidney disease, or lymphoedema — common comorbidities in long-term care — have hydration states that single-frequency BIA handles poorly. Phase angle, a direct impedance output that correlates with cellular integrity and nutritional status, is also more reliably obtained from multi-frequency devices. For clinical nutrition programs where monitoring of fluid compartments is part of the care pathway, the incremental cost of multi-frequency BIA is generally justified. See our clinical device sourcing page for supplier validation frameworks, or review the procurement process for multi-site deployments.

Integration with MUST and MNA-SF screening workflows

The Malnutrition Universal Screening Tool (MUST) and the Mini Nutritional Assessment Short Form (MNA-SF) are the two most widely used malnutrition screening instruments in hospital and aged-care settings. Both are primarily structured around clinical observation and anthropometric measurements. BIA is not a replacement for these tools; it is a complementary objective measurement that adds body-composition data to the screening decision.

In practice, BIA integration into MUST or MNA-SF workflows means using BIA output — particularly skeletal muscle index, fat-free mass, and phase angle — to flag patients who screen at medium risk on MUST or MNA-SF for dietitian review, or to monitor response to nutritional intervention over weeks or months. Procurement teams building the case for BIA should map the device outputs explicitly against the facility's nutrition care pathway, showing where BIA data enters clinical decision-making and what it replaces or supplements.

对于大多数养老机构和医院的营养评估项目，BIA是正确选择——不是因为它比DXA更准确，而是因为它是唯一可在这些场景中大规模部署的方法。EWGSOP2在其2019年更新的共识指南中明确将BIA列为无法获取DXA的临床环境中的可接受替代方案。

DXA通过双能量X射线衰减测量体成分，具有高重复性，可提供四肢瘦体质量等区域数据。BIA通过测量身体对小交流电的电阻抗来估算体成分，对水化状态敏感，个体精度低于DXA。对于养老护理中的筛查与监测目标，使用经验证设备的BIA在临床上已足够。

采购决策框架：已有DXA基础设施（用于骨密度检测）的医院，将其扩展至体成分评估边际成本低，可能是最优选择。无DXA基础设施的养老机构，BIA在资本、安装和人员成本方面均更具优势。多频BIA（BIS）在水肿、心力衰竭、慢性肾病等异常水化状态患者中优于单频设备——这在养老护理中是常见临床需求。详见临床设备采购与采购流程。

對於大多數養老機構和醫院的營養評估項目，BIA是正確選擇——不是因為它比DXA更準確，而是因為它是唯一可在這些場景中大規模部署的方法。EWGSOP2在其2019年更新的共識指南中明確將BIA列為無法獲取DXA的臨床環境中的可接受替代方案。

DXA通過雙能量X射線衰減測量體成分，具有高重複性，可提供四肢瘦體質量等區域數據。BIA通過測量身體對小交流電的電阻抗來估算體成分，對水化狀態敏感，個體精度低於DXA。對於養老護理中的篩查與監測目標，使用經驗證設備的BIA在臨床上已足夠。

採購決策框架：已有DXA基礎設施的醫院，將其擴展至體成分評估邊際成本低。無DXA基礎設施的養老機構，BIA在資本、安裝和人員成本方面均更具優勢。多頻BIA在水腫、心力衰竭等異常水化狀態患者中優於單頻設備。詳見臨床設備採購與採購流程。